Nxera Pharma announced that it had submitted an application for marketing authorization in South Korea for vamorolone, a treatment for DMD. The application was filed on the 22nd, and the company said it is targeting approval during 2027.
Nxera Pharma announced that it had submitted an application for marketing authorization in South Korea for vamorolone, a treatment for Duchenne muscular dystrophy (DMD). The drug's generic name is vamorolone. The announcement indicates that the application was submitted to the relevant authorities in South Korea.
At the time of the application, the company said it was targeting marketing authorization during 2027. No specific approval date was given, but the year was cited as the target.